What is the catalog number for Bicyclol?

The catalog number for Bicyclol is HY-B0766.

What sizes are available for Bicyclol?

Bicyclol is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg.

How many pack sizes does Bicyclol come in?

Bicyclol is available in 5 different pack sizes.

Is Bicyclol in stock?

Bicyclol is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Bicyclol?

Bicyclol is manufactured by QuantiMol.

What is the estimated delivery time for Bicyclol?

Estimated delivery time for Bicyclol is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Bicyclol?

The safety data sheet for Bicyclol is available here: http://file.medchemexpress.com/batch_PDF/HY-B0766/Bicyclol-SDS-MedChemExpress.pdf.

Bicyclol

Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma[1][2][3][4][5][6][7][8].

Product Specifications

CAS Number

118159-48-1

Product Name Alternative

SY801

UNSPSC

12352005

Hazard Statement

H410

Target

Apoptosis; Autophagy; Bcl-2 Family; CDK; Cyclin G-associated Kinase (GAK) ; ERK; Ferroptosis; Glutathione S-transferase; HBV; HCV; HSP; Interleukin Related; JNK; Microtubule/Tubulin; mTOR; NF-κB; p38 MAPK; P-glycoprotein; Reactive Oxygen Species (ROS) ; TNF Receptor

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Bicyclol.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC(OC)=C(OCO2)C2=C1C3=C4OCOC4=C(OC)C=C3CO)OC

Molecular Formula

C19H18O9

Molecular Weight

390.34

Precautions

H410

References & Citations

[1]Walsh, S.W., Y. Wang, and A. Killian, AA-2414, an antioxidant and thromboxane receptor blocker, completely inhibits peroxide-induced vasoconstriction in the human placenta. J Pharmacol Exp Ther, 1999. 290 (1) : p. 220-6.|[2]Weixin Zhao, et al. "Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways." Biomedicine & Pharmacotherapy 141 (2021) : 111874.|[3]Hui-Juan Dai, et al. "Induction of heat shock protein 27 by bicyclol attenuates d-galactosamine/lipopolysaccharide-induced liver injury." European Journal of Pharmacology 791 (2016) : 482-490.|[4]Li Hu, et al. "Bicyclol attenuates liver inflammation induced by infection of hepatitis C virus via repressing ROS-mediated activation of MAPK/NF-κB signaling pathway." Frontiers in Pharmacology 9 (2018) : 1438.|[5]Tianming Zhao, et al. "Regulating Nrf2-GPx4 axis by bicyclol can prevent ferroptosis in carbon tetrachloride-induced acute liver injury in mice." Cell death discovery 8.1 (2022) : 380.|[6]Yu Wang, et al. "Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways." BMC cancer 16 (2016) : 1-15.|[7]Tianming Zhao, et al. "Therapeutic potential of bicyclol in liver diseases: lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine." International Immunopharmacology 91 (2021) : 107308.|[8]Bing Zhu, et al. "Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated P-glycoprotein, GST-P and Bcl-2." Cancer biology & therapy 5.5 (2006) : 536-543.